Miyata et al. (2021) recently showed that administration of a SGLT2 inhibitor attenuated glomerular sclerosis and tubulointerstitial fibrosis in Ang II–treated mice independently of changes in blood pressure and GFR. These data suggest a potential role of the intrarenal RAS in the renoprotective effects of SGLT2 inhibitors (Satou et al., 2020). This evidence concerns the gene SLC5A2 and glomerulosclerosis.